Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MNCs Increasingly Investing In Diseases Affecting Developing Countries – IFPMA

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Underscoring what may be a subtle but ongoing change in focus for the industry, pharmaceutical companies appear to be increasingly focused on chronic diseases, child and maternal health and other issues of developing countries

You may also be interested in...



Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News

Paul Herrling, Head of Corporate Research at Novartis and Chairman of the Novartis Institute For Tropical Diseases, Singapore spends a week each month in Singapore and for the rest he fulfills his other global commitments. Herrling sat down with PharmAsia News in Singapore to discuss research initiatives for neglected diseases and controversies revolving around his proposal for a fund to research neglected diseases by multiple governments.

Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News

Paul Herrling, Head of Corporate Research at Novartis and Chairman of the Novartis Institute For Tropical Diseases, Singapore spends a week each month in Singapore and for the rest he fulfills his other global commitments. Herrling sat down with PharmAsia News in Singapore to discuss research initiatives for neglected diseases and controversies revolving around his proposal for a fund to research neglected diseases by multiple governments.

Indian Healthcare Industry To Zoom Past $14 Billion In The Next Three Years; Quadruple By 2017 - KPMG Report

MUMBAI - The Indian healthcare industry is estimated to double in value by 2012 at $14.2 billion and more than quadruple by 2017 from the present levels but healthcare infrastructure over the last decade has not kept pace with growth in population. This was revealed in a report, published by global management and accounting consultant KPMG, which predicts that health infrastructure across all Indian states will grow by an average 5.8 percent per annum

Related Content

UsernamePublicRestriction

Register

SC071633

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel